A recent study in JAMA Internal Medicine sheds light on persistent overtreatment of prostate cancer among men with limited life expectancy, even as active surveillance becomes more prevalent in managing low-risk cases. Researchers analysed 243,928 veterans diagnosed with localised prostate cancer between 2000 and 2019, tracking trends in overtreatment, defined as unnecessary definitive therapies like surgery or radiotherapy in patients unlikely to benefit due to shorter life expectancies.
Key Findings
- Decrease in Low-Risk Overtreatment
Among men with a life expectancy (LE) of fewer than 10 years, overtreatment of low-risk prostate cancer decreased significantly—from 37.4% in 2000 to 14.7% in 2019. This decline reflects a growing adoption of active surveillance strategies, which emphasize monitoring over immediate intervention for low-risk cases. - Increase in Intermediate- and High-Risk Overtreatment
In contrast, overtreatment increased in men with intermediate- and high-risk prostate cancer who had limited life expectancy. For those with an LE of fewer than 10 years, treatment rates for intermediate-risk disease rose from 37.6% to 59.8%. Similarly, definitive treatment for high-risk prostate cancer among men with an LE of fewer than 5 years surged from 17.3% to 46.5%. - Predominance of Radiotherapy
Radiotherapy emerged as the primary treatment, especially in men with limited life expectancy. Among patients receiving definitive therapy, 78% with an LE of fewer than 10 years and 85% with an LE of fewer than 5 years underwent radiotherapy. The use of radiotherapy increased steadily for intermediate- and high-risk disease, even in individuals unlikely to live long enough to benefit significantly.
Implications for Clinical Practice
The findings reveal a concerning pattern: while overtreatment of low-risk prostate cancer has diminished, clinicians continue to offer aggressive therapies to men with intermediate- and high-risk cancers, even when their limited life expectancy precludes meaningful benefit. Such interventions not only fail to improve outcomes but also expose patients to unnecessary toxicities, including fatigue, urinary dysfunction, and bowel issues.
The study calls for stricter adherence to guidelines that discourage definitive treatment in men with limited life expectancy. Clinicians are urged to balance tumor risk against individual longevity when recommending treatment, reserving aggressive therapies for patients likely to benefit.
A Path Forward
As active surveillance gains traction for low-risk prostate cancer, extending this mindset to intermediate- and high-risk cases in men with limited life expectancy is crucial. Ongoing education, shared decision-making, and refined prognostic tools may help clinicians navigate these complex decisions, reducing overtreatment while preserving quality of life for patients.
The study underscores a broader challenge in cancer care: the need to align treatment intensity with patient prognosis, minimising harm while optimizing outcomes.
